REVIEW PAPER
Angiogenesis modulation by exogenous antioxidants
More details
Hide details
Submission date: 2017-10-30
Acceptance date: 2017-10-31
Publication date: 2017-12-30
Cent Eur J Immunol 2017;42(4):370-376
KEYWORDS
ABSTRACT
Co-operation of the endogenous and exogenous defense system maintains redox homeostasis and is essential for health. The endogenous defense system includes enzymatic (e.g. superoxide dismutase, catalase) and non-enzymatic, low molecular-weight scavengers (e.g. glutathione, ascorbic acid). Pathogenesis of many serious diseases (e.g. cancer, ischemic heart disease) includes oxidative stress which can disturb angiogenesis, the process of formation of new blood vessels sprouting from the existing one. Antioxidants, through reduction of oxidative stress and influence on neovascularization, may modulate progress and results of therapy in those diseases where such processes play an important role. Herein the impact of exogenous antioxidants on angiogenesis and factors modulating this process is presented. Most synthetic antioxidants whose activity has been described (namely N-acetylcysteine, pentoxifylline, synthetic analogue of curcumin, synthetic analogue of epigallocatechin-3 gallate [EGCG], tripertenoids) exert an inhibitory effect on neovascularization. A similar effect was also exhibited by several natural origin antioxidants (e.g. resveratrol, EGCG), which suggests that their application in therapy might normalize excessive angiogenesis. Some natural origin antioxidants e.g. purple coneflower and preparations consisting of natural antioxidants such as Padma 28 and Immunal forte increase a too low baseline level of angiogenesis and decreases a too high level. These preparations exert a regulatory effect on and may normalize neovascularization. They can be used in the case of diseases associated with too low or too high angiogenesis.
REFERENCES (57)
1.
Devasagayam TP, Tilak JC, Boloor KK, et al. (2004): Free radicals and antioxidant in human health: current status and future prospects. JAPI 52: 794-804.
2.
Radomska-Leśniewska DM, Hevelke A, Skopiński P, et al. (2016): Reactive oxygen species and synthetic antioxidants as angiogenesis modulators. Pharmacol Rep 68: 462-471.
3.
Carmeliet P, Jain RK (2011): Molecular mechanisms and clinical applications of angiogenesis. Nature 473: 298-307.
4.
Brambilla D, Mancuso C, Scuderi MR, et al. (2008): The role of antioxidant supplement in immune system, neoplastic, and neurodegenerative disorders: a point of view for an assessment of the risk/ benefit profile. Nutr J 30: 7-29.
5.
Sadowska AM, Manuel-Y-Keenoy B, De Backer WA (2007): Antioxidant and anti-inflammatory efficacy of NAC in the treatment of COPD: discordant in vitro and in vivo dose-effects: a review. Pulm Pharmacol Ther 20: 9-22.
6.
Halliwell B (1999): Antioxidant defence mechanisms: from the beginning to the end (of the beginning). Free Radic Res 31: 261-272.
7.
Valko M, Leibfritz D, Moncol J, et al. (2007): Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol 39: 44-84.
8.
Radomska-Leśniewska DM, Skopińska-Różewska E, Jankowska-Steifer E, et al. (2010): N-acetylcysteine inhibits IL-8 and MMP-9 release and ICAM-1 expression by bronchoalveolar cells from interstitial lung diseases patients. Pharmacol Rep 2010; 62: 131-138.
9.
Radomska-Leśniewska DM, Sadowska AM, van Overveld F, et al. (2006): Influence of N-acetylcysteine on ICAM-1 expression and IL-8 release from endothelial and epithelial cells. J Physiol Pharmacol 57 Suppl 4: 325-334.
10.
Henry MT, McMahon K, Mackarel AJ, et al. (2002): Matrix metalloproteinases and tissue inhibitor of metalloproteinase-1 in sarkoidosis and IPF. Eur Resp J 20: 1220-1227.
11.
Ishii Y, Kitamura S (1995): Elevated level of soluble ICAM in serum and BAL fluid in patient with active sarcoidosis. Chest 107: 1636-1640.
12.
Martines FO, Gordon S (2014): The M1 and M2 paradigm of macrophage activation: time for rassessment. F1000 Prime Repp 6: 13.
13.
Zafarullah M, Li WQ, Sylvester J, Ahmad M (2003): Molecular mechanisms of N-acetylcysteine actions. Cell Mol Life Sci 60: 6-20.
14.
Gao P, Zhang G, Dinavahi R, et al. (2007): HIF-dependent anti-tumorigenic effect of anti-oxidants in vivo. Cancer Cell 12: 230-238.
15.
Fan X, Zhang C, Liu DB, et al. (2013): The clinical applications of curcumin: current state and the future. Curr Pharm Des 19: 2011-2031.
16.
Prauchner CA (2014): Angiogenesis inhibition by antioxidants. Internat J Biomed Science and Engineer 2: 7-19.
17.
Wang YY, Zhe H, Zhao R, et al. (2014): Preclinical evidences toward the use of triterpenoid CDDO-Me for solid cancer prevention and treatment. Mol Cancer 13: 30.
18.
Wang CC, Xu H, Man GC, et al. (2013): Prodrug of green tea epigallocatechin-3-gallate (Pro-EGCG) as a potent antiangiogenesis agent for endometriosis in mice. Angiogenesis 16: 59-69.
19.
Deree J, Martins JO, Melbostad H, et al. (2008): Insights into the regulation of TNF-αlpha production in human mononuclear cells: the effects of non-specific phosphodiesterase inhibition. Clinics 63: 321-328.
20.
Marques LJ, Zheng L, Poulakis N, Guzman J, Costabel U (1999): Pentoxifylline inhibits TNF-αlpha production from human alveolar macrophages. Am J Respir Crit Care Med 159: 508-511.
21.
Peters-Golden M, Canetti C, Mancuso P, Coffey MJ (2005): Leukotrienes: underappreciated mediators of innate immune responses. J Immunol 174: 589-594.
22.
Rezvanfar MA, Saadat S, Shojaei Saadi HA, et al. (2015): Cellular and molecular mechanisms of pentoxifylline’s beneficial effects in experimental polycystic ovary. Theriogenol 83: 968-977.
23.
Bałan BJ, Demkow U, Skopiński P, et al. (2017): The effect of pentoxifylline on L-1 sarcoma tumor growth and angiogenesis in Balb/c mice. Cent Eur J Immunol 42: 131-139.
24.
Kamran MZ, Gude ROP (2013): Pentoxifylline inhibits melanoma tumor growth and angiogenesis by targeting STAT3 signaling pathway. Biomed Pharmacother 67: 399-405.
25.
Lazarczyk M, Grzela T, Niderla J, et al. (2004): Differential influence of pentoxifylline on murine colon adenocarcinoma- and melanoma-derived metastatic tumor development in lungs. Oncol Rep 11: 1121-1125.
26.
Grzela T, Lazarczyk M, Niderla J, et al. (2003): Pentoxifylline promotes development of murine colon adenocarcinoma-derived metastatic tumors in liver. Oncol Rep 10: 1805-1809.
27.
Lazarczyk M, Grzela T, Niderla J, et al. (2003): Pentoxifylline inhibits leukocyte infiltration and splenocyte cytotoxicity against murine colon adenocarcinoma. Oncol Rep 10: 839-843.
28.
Lazarczyk M, Grzela T, Korczak-Kowalska G, et al. (2002): Pentoxifylline inhibits perforin-dependent natural cytotoxicity in vitro. Oncol Rep 9: 423-426.
29.
Polytarchou C, Papadimitriou E (2005): Anioxidants inhibit human endothelial cell functions through down-regulation of the endothelial nitric oxide synthetase activity. Eur J Pharmacol 510: 31-38.
30.
Radomska-Leśniewska DM, Skopiński P, Bałan BJ, et al. (2015): Angiomodulatory properties of Rhodiola spp. and other natural antioxidants. Centr Eur J Immunol 40: 249-262.
31.
Skopińska-Różewska E, Sommer E, Bałan B, et al. (2010): The in vivo effect of dry hydro-alcoholic extract of Echinacea purpurea on angiogenic activity of human blood mononuclear cells. Centr Eur J Immunol 35: 223-226.
32.
Rogala E, Skopińska-Różewska E, Wasiutyński A, et al. (2008): Echinacea purpurea diminishes neovascular reaction induced in mice skin by human cancer cells and stimulates non-specific cellular immunity in humans. Centr Eur J Immunol 33: 127-130.
33.
Bany J, Siwicki AK, Zdanowska D, et al. (2003): Echinacea purpurea stimulates cellular immunity and anti-bacterial defence independently of the strain of mice. Pol J Vet Sci 6 (Suppl 3): 3-5.
34.
Wasiutyński A, Bałan B, Skopińska-Różewska E, et al. (2009): The effect of Echinacea purpurea on the morphology, angiogenic activity and vascular endothelial growth factor (VEGF) concentration of murine L-1 sarcoma tumors. Centr Eur J Immunol 34: 38-41.
35.
Skopiński P, Radomska-Leśniewska DM, Sokolnicka I, et al. (2013): In vivo stimulatory effect of multi-component herbal remedy PADMA 28 on mitogen-induced proliferation of mice splenic lymphocytes and their chemokinetic activity. Pol J Vet Sci 4: 701.
36.
Radomska-Leśniewska DM, Skopiński P, Niemcewicz M, et al. (2013): The effect of anti-inflammatory and antimicrobial herbal remedy PADMA 28 on immunological angiogenesis and granulocytes activity in mice. Mediators of Inflammation 2013: 853475.
37.
Ginsburg I, Rozenstein-Tsalkovich L, Koren E, Rosenmann H (2011): The herbal preparation Padma 28 protects against neurotoxicity in PC12 cells. Phytother Res 25: 740-748.
38.
Skopińska-Różewska E, Pastewka K, Wasiutyński A, et al. (2010): The influence of herbal remedies on cutaneous angiogenesis induced in mice after grafting of human kidney cancer tissue. Centr Eur J Immunol 35: 199-203.
39.
Kim EJ, Hong JE, Lim SS, et al. (2012): The hexane extract of Saussurea lappa and its active principle, dehydrocostus lactone, inhibit prostate cancer cell migration. J Med Food 15: 24-32.
40.
Wang CY, Tsai AC, Peng CY, et al. (2012): Dehydrocostuslactone suppresses angiogenesis in vitro and in vivo through inhibition of AKT/GSK-3beta and mtor signaling pathways. PLoS One 7: e31195.
41.
Radomska-Leśniewska DM, Skopińska-Różewska E, Demkow U, et al. (2016): Natural herbal remedy modulates angiogenic activity of bronchoalveolar lavage cells from sarcoidosis patients. Centr Eur J Immunol 41: 25-30.
42.
Bråkenhielm E, Cao R, Cao Y (2001): Suppression of angiogenesis, tumor growth, and wound healing by resveratrol, a natural compound in red wine and grapes. FASEB J 15: 1798-1800.
43.
Prauchner CA (2014): Angiogenesis inhibition by antioxidants. Intern J Biomed Scien Engineer 2: 7-19.
44.
Park DW, Baek K, Kim JR, et al. (2009): Resveratrol inhibits foam cell formation via NADPH oxidase 1-mediated reactive oxygen species and monocyte chemotactic protein-1. Exp Mol Med 41: 171-179.
45.
Ushio-Fukai M, Tang Y, Fukai T, et al. (2002): Novel role of gp91phox-containing NAD(P)H oxidase in vascular endothelial growth factor-induced signaling and angiogenesis. Circ Res 91: 1160-1167.
46.
Diebold I, Petry A, Hess J, Görlach A (2010): The NADPH oxidase subunit NOX4 is a new target gene of the hypoxia-inducible factor-1. Mol Biol Cell 10: 2087-2096.
47.
Seong H, Ryu J, Jeong JY, et al. (2015): Resveratrol suppresses VEGF secretion via inhibition of CXC-chemokine receptor 4 expression in ARPE-19 cells. Mol Med Rep 12: 1479-1484.
48.
George J, Singh M, Srivastava AK, et al. (2011): Resveratrol and black tea polyphenol combination synergistically suppress mouse skin tumors growth by inhibition of activated MAPKs and p53. PLoS One 6: e23395.
49.
Lee SH, Koo BS, Park SY, Kim YM (2015): Anti-angiogenic effects of resveratrol in combination with 5-fluorouracil on B16 murine melanoma cells. Mol Med Rep 12: 2777-2783.
50.
Szaflik JP, Stańczyk M, Skłodowska A, et al. (2013): Resveratrol may reduce oxidative stress in AMD patients. SOE 8-11 June 2013. Copenhagen, Denmark; Poster EP_RET-739.
51.
Cao Y, Cao R (1999): Angiogenesis inhibited by drinking tea. Nature 398: 381.
52.
Yang CS, Chen L, Lee MJ, et al. (1998): Blood and urine levels of tea catechins after ingestion of different amounts of green tea by human volunteers. Cancer Epidemiol Biomark Prev 7: 351-354.
53.
Dona M, Dell’Aica I, Calabrese F, et al. (2003): Neutrophil restraint by green tea: inhibition of inflammation, associated angiogenesis, and pulmonary fibrosis. J Immunol 170: 4335-4341.
54.
Maeda-Yamamoto M, Kawahara H, Tahara N, et al. (1999): Effects of tea polyphenols on the invasion on the matrix metalloproteinases acitivities of human fibrosarcoma HT1080 cells. J Agric Food Chem 47: 2350-2354.
55.
Zhang G, Miura Y, Yagasaki K (2000): Supression of adhesion through antioxidative activity and invasion of hepatoma cell in culture by tea compounds adhesion. Cancer Lett 159: 169-173.
56.
Jung YD, Kim MS, Shin BA, et al. (2001): EGCG, a major component of green tea, inhibits tumour growth by inhibiting VEGF induction in human colon carcinoma cells. Br J Cancer 84: 844-850.
57.
Dong Z, Ma WY, Huang C, Yang CS (1997): Inhibition of tumour promoter-induced activator protein 1 activation and cell transformation by tea polyphenols, (-)-epigallocatechin gallate, and theaflavins. Cancer Res 57: 4414-4419.